Project Grant R21DA066282
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $466K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- The National Institute of Neurological Disorders and Stroke awarded Weill Medical College of Cornell University $466,125 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to develop and benchmark ACCENT (Acyclovir-Controlled Calcium Entry Neuromodulation Tool), a chemogenetic platform for selective, reversible, and dose-dependent control of L-type calcium channels in neurons using the FDA-approved drug acyclovir. The...
- The National Institute of Neurological Disorders and Stroke awarded Weill Medical College of Cornell University $635,074 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop HCN1-selective nanobodies for use in novel, non-opioid antihyperalgesia therapeutics targeting neuropathic pain. The project focuses on creating an HCN1-selective nanobody and identifying critical geometric features of the human HCN1 ion channel to guide antibody-drug conjugate...
- The National Institute of Neurological Disorders and Stroke awarded Massachusetts General Hospital $1.130557 million on August 20, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop a non-viral lipid nanoparticle-delivered gene therapy for acute pain treatment as an alternative to opioids. The project focuses on creating a focal-delivery, non-opioid therapeutic targeting postsurgical pain as the primary indication, with secondary applications to acute exacerbations...
- The National Institute of Neurological Disorders and Stroke awarded the University of Massachusetts Lowell $2.272 million on June 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to discover novel, non-opioid, non-addictive analgesics derived from marine microbial natural products. The award funds a phenotypic screening effort combining human induced pluripotent stem cell sensory neurons and glia cultured on multi-well microelectrode arrays to characterize sensory neuron...
- This $1,563,778 Project Grant was awarded by the National Institute of Neurological Disorders and Stroke under the NIH's Drug Use and Addiction Research Programs (CFDA 93.279) on September 12, 2024. The grant supports research conducted by Duke University to develop equilibrative nucleoside transporter (ENT1) inhibitors as potential non-opioid pain therapeutics. The project aims to: 1) validate ENT1 as a novel target for neuropathic pain treatment, 2) characterize a novel ENT1 inhibitor compound...
- The National Institute on Drug Abuse awarded Icahn School of Medicine at Mount Sinai $2.35 million on February 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to mine transcriptomic datasets and resolve functionally relevant striatal cell types in response to HIV infection and opioid use. The recipient will analyze single-nucleus RNA sequencing, two-dimensional single-cell spatial transcriptomic, and three-dimensional single-cell spatial transcriptomic data generated...
- The National Institute on Drug Abuse awarded Virginia Commonwealth University $426,938 on June 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate whether astrocyte elevated gene-1 (AEG-1) functions as an endogenous anti-opioid regulator that could improve the safety and efficacy of opioid analgesics. The research examines AEG-1's role in regulating morphine antinociceptive tolerance through peripheral neuronal sensory neuroinflammatory mechanisms. The...
- The National Institute on Drug Abuse awarded Icahn School of Medicine at Mount Sinai $796,299 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct single chromatin fiber multiomic mapping in opioid use disorder brain tissue. The recipient will perform genome-wide profiling of chromatin organization directly from frontal and cingulate cortex nuclei obtained from donors with chronic opioid use disorder. The work charts nucleosomal array organization,...
- The National Institute on Drug Abuse awarded Icahn School of Medicine at Mount Sinai $100,228 on October 8, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support research on opioid reward mechanisms. The award funds a project investigating the functional role of a novel cortical circuit connecting the dorsal peduncular nucleus to the ventral tegmental area in mediating opioid reward. The research employs barcoded anatomy resolved by sequencing combined with spatial...
- The National Institute of Neurological Disorders and Stroke awarded the University of Rochester $2,197,287 on August 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a Phase III confirmatory clinical trial of daily, wireless, home-based transcutaneous electrical nerve stimulation (TENS) for chemotherapy-induced peripheral neuropathy (CIPN). The trial will evaluate TENS efficacy in relieving neuropathic pain in cancer patients who have developed CIPN—a common...